VANCOUVER, British Columbia, June 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the dose-escalation portion of its ongoing Phase 1 study evaluating ZW191, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2026.
GOTHENBURG, Sweden, June 13, 2026 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company committed to developing core tools and technologies that drive innovation...
DUBAI, UAE, June 13, 2026 /PRNewswire/ -- This is why Junkies Coder UAE-based Company has launched its Agentic AI & Enterprise Modernisation practice —...
Bitmine's Board of Directors declares initial cash dividends on the Company's 9.50% Series A Perpetual Preferred StockSeries A Preferred Stock approved for listing on...
Association supports initiative but asks for longer transition periods and clear guidanceTORONTO, June 12, 2026 /CNW/ - The Securities and Investment Management Association (SIMA)...
WASHINGTON, June 12, 2026 /PRNewswire/ -- ELIQUENT Life Sciences ("ELIQUENT") today announced the June 1 go-live of Veeva Safety Suite at UCB. As one...
WASHINGTON, June 12, 2026 /PRNewswire/ -- ELIQUENT Life Sciences ("ELIQUENT") today announced the June 1 go-live of Veeva Safety Suite at UCB. As one...
WASHINGTON, June 12, 2026 /PRNewswire/ -- ELIQUENT Life Sciences ("ELIQUENT") today announced the June 1 go-live of Veeva Safety Suite at UCB. As one...
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Via To Contact Him Directly To Discuss Their Options